Olivia Brayer
Stock Analyst at Cantor Fitzgerald
(2.18)
# 3,224
Out of 4,639 analysts
129
Total ratings
42%
Success rate
1.1%
Average return
Main Sectors:
Stocks Rated by Olivia Brayer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSM Insmed | Maintained: Buy | $235 | $134.75 | +74.40% | 5 | Aug 6, 2026 | |
| VNDA Vanda Pharmaceuticals | Reiterated: Buy | $11 | $5.02 | +119.12% | 6 | Aug 6, 2026 | |
| MNKD MannKind | Maintained: Buy | $9 → $8 | $3.93 | +103.56% | 5 | Aug 5, 2026 | |
| TENX Tenax Therapeutics | Maintained: Buy | $35 | $1.38 | +2,445.45% | 3 | Jul 29, 2026 | |
| QNCX Quince Therapeutics | Initiated Coverage: Buy | $80 | $30.65 | +161.01% | 1 | Jun 25, 2026 | |
| CNTB Connect Biopharma Holdings | Initiated Coverage: Buy | $4 | $2.15 | +86.05% | 1 | May 21, 2026 | |
| IKT Inhibikase Therapeutics | Maintained: Buy | $4 | $2.46 | +62.60% | 2 | May 18, 2026 | |
| PTHS Pelthos Therapeutics | Initiated Coverage: Buy | $50 | $29.00 | +72.41% | 1 | Apr 1, 2026 | |
| CTMX CytomX Therapeutics | Maintained: Buy | $10 → $12 | $3.44 | +248.84% | 5 | Mar 20, 2026 | |
| GOSS Gossamer Bio | Downgraded: Hold | n/a | $0.1761 | - | 6 | Mar 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $525 → $625 | $529.66 | +18.00% | 4 | Mar 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $85 | $68.88 | +23.40% | 18 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $450 → $400 | $216.98 | +84.35% | 11 | Feb 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $480 | $523.91 | n/a | 23 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $405 → $340 | $417.20 | n/a | 4 | Feb 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $52 → $55 | $64.84 | n/a | 8 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $70 → $80 | $133.06 | n/a | 8 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $795 → $925 | $808.05 | n/a | 4 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $15 → $10 | $15.45 | n/a | 6 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $13.62 | n/a | 1 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $53.51 | n/a | 3 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $3 | $5.36 | n/a | 4 | Mar 20, 2023 |
Insmed
Aug 6, 2026
Maintained: Buy
Price Target: $235
Current: $134.75
Upside: +74.40%
Vanda Pharmaceuticals
Aug 6, 2026
Reiterated: Buy
Price Target: $11
Current: $5.02
Upside: +119.12%
MannKind
Aug 5, 2026
Maintained: Buy
Price Target: $9 → $8
Current: $3.93
Upside: +103.56%
Tenax Therapeutics
Jul 29, 2026
Maintained: Buy
Price Target: $35
Current: $1.38
Upside: +2,445.45%
Quince Therapeutics
Jun 25, 2026
Initiated Coverage: Buy
Price Target: $80
Current: $30.65
Upside: +161.01%
Connect Biopharma Holdings
May 21, 2026
Initiated Coverage: Buy
Price Target: $4
Current: $2.15
Upside: +86.05%
Inhibikase Therapeutics
May 18, 2026
Maintained: Buy
Price Target: $4
Current: $2.46
Upside: +62.60%
Pelthos Therapeutics
Apr 1, 2026
Initiated Coverage: Buy
Price Target: $50
Current: $29.00
Upside: +72.41%
CytomX Therapeutics
Mar 20, 2026
Maintained: Buy
Price Target: $10 → $12
Current: $3.44
Upside: +248.84%
Gossamer Bio
Mar 20, 2026
Downgraded: Hold
Price Target: n/a
Current: $0.1761
Upside: -
Mar 12, 2026
Initiated Coverage: Buy
Price Target: $525 → $625
Current: $529.66
Upside: +18.00%
Mar 2, 2026
Maintained: Buy
Price Target: $85
Current: $68.88
Upside: +23.40%
Feb 12, 2026
Maintained: Hold
Price Target: $450 → $400
Current: $216.98
Upside: +84.35%
Feb 11, 2025
Reiterated: Buy
Price Target: $480
Current: $523.91
Upside: n/a
Feb 5, 2025
Maintained: Buy
Price Target: $405 → $340
Current: $417.20
Upside: n/a
Feb 4, 2025
Maintained: Hold
Price Target: $52 → $55
Current: $64.84
Upside: n/a
Nov 6, 2024
Maintained: Hold
Price Target: $70 → $80
Current: $133.06
Upside: n/a
Apr 17, 2024
Maintained: Hold
Price Target: $795 → $925
Current: $808.05
Upside: n/a
Feb 23, 2024
Maintained: Buy
Price Target: $15 → $10
Current: $15.45
Upside: n/a
Nov 10, 2023
Downgraded: Hold
Price Target: n/a
Current: $13.62
Upside: n/a
Oct 17, 2023
Downgraded: Hold
Price Target: n/a
Current: $53.51
Upside: n/a
Mar 20, 2023
Maintained: Hold
Price Target: $3
Current: $5.36
Upside: n/a